UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant   ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☒	Definitive Additional Materials
☐	Soliciting Material Pursuant to §240.14a-12

EyePoint Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒	No fee required.
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

Materials EyePoint Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.   To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 13, 20

20.

SUPPLEMENT #1 TO DEFINITIVE PROXY STATEMENT

On or about May 8, 2020, EyePoint Pharmaceuticals, Inc.,aDelawarecorporation(the“Company,”“we,”“us”or“our”)sent outproxymaterialsto stockholderswhoheldtheCompany’scommonstockasofApril 24,2020(the“RecordDate”),includingaNoticeofAnnualMeeting ofStockholders with instructions for online access to our proxystatement(the“OriginalProxyStatement”),forthe2020AnnualMeetingofStockholders (the “Annual Meeting”), that is to be held on Tuesday, June 23, 2020, at 9:00 a.m., Eastern Time, for the purposes set forth in the Original ProxyStatement.

Although the Original Proxy Statement relating to the Annual Meeting stated that David Guyer, M.D. had attended approximately 65% of the meetings of the Board and those committees on which he was a member during 2019, these statements were an error on our part.

Following the filing of the Original Proxy Statement, we re-examined our calculations regarding Dr. Guyer’s attendance and determinedthatwe had erroneously marked Dr. Guyer absent from meetings of certain Board committees on which he was not yet a member,andasaresultwemiscalculatedhisattendancerecord.Infact, Dr. Guyer hadattended 100%ofthemeetingsoftheBoard andtheBoardcommitteesonwhichhewasamemberduring2019.

In light of this correction regarding Dr. Guyer’s attendance, the Board reiterates its recommendation that stockholders vote “FOR” Dr. Guyer’s election to the Board, in addition to the other director nominees.

Exceptassupplementedbytheinformationcontainedinthis FirstSupplement,allinformationsetforthintheOriginalProxyStatementremainsaccurateinallmaterialrespectsandshouldbeconsideredincastingyourvotebyproxyor at the AnnualMeeting.